IKT (Inhibikase Therapeutics) General and Admin. Expense: $0.00 Mil (TTM As of Mar. 2026)


IKT Inhibikase Therapeutics Inc IKT
34 GF Score
Price $2.03
! 1 Warning Sign
View Full Analysis

What is Inhibikase Therapeutics General and Admin. Expense?

Inhibikase Therapeutics IKT +5.45% 34 General and Admin. Expense is $0.00 Mil as of Mar. 2026. GuruFocus rates IKT with a GF Score™ of 34/100. The stock has 1 warning sign investors should review.

General and Admin. Expense is the aggregate total of general managing and administering expenses for the company. Inhibikase Therapeutics's General and Admin. Expense for the three months ended in Mar. 2026 was $0.00 Mil. Its General and Admin. Expense for the trailing twelve months (TTM) ended in Mar. 2026 was $0.00 Mil.

Inhibikase Therapeutics General and Admin. Expense Related Terms

Inhibikase Therapeutics General and Admin. Expense Historical Data

* Premium members only.

The historical data trend for Inhibikase Therapeutics's General and Admin. Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Inhibikase Therapeutics General and Admin. Expense Chart

Inhibikase Therapeutics Annual Data
Trend Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
General and Admin. Expense
Get a 7-Day Free Trial 0.00 0.00 0.00 0.00 0.00

Inhibikase Therapeutics Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
General and Admin. Expense Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00
IKT
34GF Score
Inhibikase Therapeutics Inc IKT
General and Admin. Expense is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Inhibikase Therapeutics General and Admin. Expense Calculation

General and Admin. Expense is the aggregate total of general managing and administering expenses for the company.

General and Admin. Expense for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.00 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

What does a General and Admin. Expense of $0.00 Mil mean?
Inhibikase Therapeutics (IKT) has a General and Admin. Expense of $0.00 Mil as of Mar. 2026. General and Admin. Expense is the aggregate total of general managing and administering expenses for the company. View historical data on Inhibikase Therapeutics and its competitors.
Is Inhibikase Therapeutics' General and Admin. Expense too high?
Inhibikase Therapeutics' current General and Admin. Expense is $0.00 Mil. Overall, Inhibikase Therapeutics has a GF Score™ of 34/100, reflecting its overall financial health beyond just this single metric.
How does Inhibikase Therapeutics' General and Admin. Expense compare to FHTX and OBIO?
Inhibikase Therapeutics' General and Admin. Expense of $0.00 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good General and Admin. Expense for a Biotechnology company?
A good General and Admin. Expense depends on the Biotechnology industry context. However, General and Admin. Expense should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high General and Admin. Expense mean?
A high General and Admin. Expense can signal that a stock is expensive relative to its fundamentals. General and Admin. Expense is the aggregate total of general managing and administering expenses for the company. View historical data on Inhibikase Therapeutics and its competitors. Inhibikase Therapeutics's current General and Admin. Expense is $0.00 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Inhibikase Therapeutics stock overvalued right now?
Inhibikase Therapeutics (IKT) has a current General and Admin. Expense of $0.00 Mil. The current General and Admin. Expense is $0.00 Mil. Inhibikase Therapeutics' overall GF Score™ is 34/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is General and Admin. Expense calculated?
General and Admin. Expense is calculated from a company's financial statements. For Inhibikase Therapeutics (IKT), the current General and Admin. Expense is $0.00 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Inhibikase Therapeutics Business Description

Address 1000 N. West Street, Suite 1200, Wilmington, DE, USA, 19801
Inhibikase Therapeutics Inc a clinical-stage pharmaceutical company developing therapeutics to modify the course of cardiopulmonary diseases, namely, Pulmonary Arterial Hypertension (PAH), in which aberrant signaling through type III receptor tyrosine kinases, including platelet derived growth factor receptors and a stem cell factor receptor, known as c-Kit, has been implicated. Its product candidate is IKT-001, a prodrug of imatinib mesylate (imatinib), for PAH which is an orphan indication. The company has developed its own portfolio of protein kinase inhibitors to treat bacterial and viral infections, including viral infections in the brain. It has one reporting segment, which is the business of developing protein kinase inhibitor therapeutics.
34GF Score

Get the complete analysis for IKT

General and Admin. Expense is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$2.03
Price